Inovio Pharmaceuticals Inc Share Price NYSE
Stocks
US45773H1023
Biotechnology & Medical Research
|
End-of-day quote
NYSE
|
||
| - USD | - |
|
| Market Cap | 330M 300M 277M 252M 472M 30.53B 496M 3.37B 1.34B 16.67B 1.24B 1.21B 52.33B | P/E 2026 * |
-1.96x | P/E 2027 * | -9.96x |
|---|---|---|---|---|---|
| Enterprise Value | 330M 300M 277M 252M 472M 30.53B 496M 3.37B 1.34B 16.67B 1.24B 1.21B 52.33B | EV / Sales 2026 * |
944x | EV / Sales 2027 * | 3.93x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Inovio Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 60 | 09/05/2022 |
Peter Kies
DFI | Director of Finance/CFO | 62 | 31/05/2002 |
Michael Sumner
CTO | Chief Tech/Sci/R&D Officer | 60 | 26/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Simon Benito
CHM | Chairman | 81 | 02/01/2019 |
David Weiner
BRD | Director/Board Member | 69 | 10/03/2016 |
Wendy Yarno
BRD | Director/Board Member | 71 | 05/12/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.49% | -3.76% | +50.31% | +62.10% | 63.66B | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 58.56B | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 54.19B | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 44.66B | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 40.51B | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 36.27B | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 34.89B | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 32.26B | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 31.01B | ||
| Average | -1.37% | -1.22% | +33.67% | +175.26% | 44B | |
| Weighted average by Cap. | -1.48% | -1.85% | +32.16% | +150.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 349K 318K 293K 267K 500K 32.35M 526K 3.57M 1.42M 17.67M 1.31M 1.28M 55.45M | 83.88M 76.4M 70.4M 64.04M 120M 7.77B 126M 857M 341M 4.24B 315M 308M 13.32B |
| Net income | -91.28M -83.14M -76.61M -69.69M -131M -8.45B -137M -932M -371M -4.62B -342M -335M -14.49B | -34.22M -31.16M -28.72M -26.12M -49M -3.17B -51.5M -350M -139M -1.73B -128M -126M -5.43B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
















